Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9


Tumour-suppression function of KLF12 through regulation of anoikis.

Godin-Heymann N, Brabetz S, Murillo MM, Saponaro M, Santos CR, Lobley A, East P, Chakravarty P, Matthews N, Kelly G, Jordan S, Castellano E, Downward J.

Oncogene. 2016 Jun 23;35(25):3324-34. doi: 10.1038/onc.2015.394. Epub 2015 Oct 12.


Phosphorylation of ASPP2 by RAS/MAPK pathway is critical for its full pro-apoptotic function.

Godin-Heymann N, Wang Y, Slee E, Lu X.

PLoS One. 2013 Dec 2;8(12):e82022. doi: 10.1371/journal.pone.0082022. eCollection 2013.


ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells.

Wang Y, Godin-Heymann N, Dan Wang X, Bergamaschi D, Llanos S, Lu X.

Cell Death Differ. 2013 Apr;20(4):525-34. doi: 10.1038/cdd.2013.3. Epub 2013 Feb 8.


HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis.

Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N, Gross KW, Vivanco Md, Wijendran V, Shioda T, Sgroi D, Donahoe PK, Maheswaran S.

Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1100-5. doi: 10.1073/pnas.0912710107. Epub 2009 Dec 28.


The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.

Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DA.

Mol Cancer Ther. 2008 Apr;7(4):874-9. doi: 10.1158/1535-7163.MCT-07-2387.


Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation.

Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ 2nd, Settleman J, Haber DA.

Cancer Res. 2007 Aug 1;67(15):7319-26.


Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.

Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J.

Cold Spring Harb Symp Quant Biol. 2005;70:419-26. Review.


Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA.

Nat Genet. 2005 Dec;37(12):1315-6. Epub 2005 Oct 30.


Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70. Epub 2005 May 16.

Supplemental Content

Loading ...
Support Center